This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E75.1 (other gangliosidosis) | Special Copayment Reduction: V117 (ultra-rare disease) |
| B. Synonyms | GM₃ gangliosidosis, ST3GAL5 deficiency, lactosylceramide sialyltransferase deficiency, Amish infantile epilepsy syndrome, GM3 synthase deficiency |
| C. Adult onset | Likelihood of first onset in adulthood: none (ultra-rare infantile-onset disease) — all reported cases begin with infantile epilepsy and developmental regression with onset within the first few months of life, and no adult-onset cases have been reported. |
| 1. History | 2004 Simpson et al. describe an infantile epilepsy and developmental regression syndrome in the US Old Order Amish population → 2004 ST3GAL5 gene variant identified → GM3 ganglioside synthase deficiency confirmed. |
| 2. Causes | ST3GAL5 gene variants → loss of function of GM3 synthase (lactosylceramide sialyltransferase) → inability to synthesize GM3 and more complex gangliosides (GM2, GM1, GD1a, etc.) → ganglioside deficiency in neuronal membranes. |
| 3. Genetics | ST3GAL5 gene (2p11.2), autosomal recessive. Founder variant in the Amish population: p.Arg288Ter. Various missense and splicing variants reported in non-Amish patients. The rarest of the ganglioside synthesis deficiency disorders. |
| 4. General epidemiology | Several dozen cases reported worldwide (extremely ultra-rare). Concentrated in the Old Order Amish population (founder effect). Estimated at fewer than 30–50 cases worldwide. No reports or very few in Korea. |
| 5. Pathophysiology | GM3 synthase deficiency → blocked synthesis of all a-series and b-series gangliosides downstream of GM3 → complete ganglioside deficiency in neuronal membranes → abnormal neural development, synaptic dysfunction, demyelination, and epilepsy. |
| 6. Symptoms | Severe infantile spasms, hypertonia, and developmental regression within the first few months after birth. Skin: ichthyosis-like hyperkeratosis. Visual impairment. Status epilepticus. Heat sensitivity (seizures worsen with fever). |
| 7. Signs | Hypertonia and spasticity, recurrent seizures (West syndrome pattern), skin scaling, corneal opacity; brain MRI: demyelination and abnormal brain development. EEG: hypsarrhythmia. |
| 8. Screening | Amish population: detection of the ST3GAL5 founder variant. No screening of the general population. With clinical suspicion, plasma and cerebrospinal fluid ganglioside profile + ST3GAL5 gene analysis. |
| 9. Diagnosis | Plasma and red cell membrane ganglioside analysis (loss of GM3 + loss of all complex gangliosides). ST3GAL5 gene analysis. Ganglioside analysis of skin biopsy. Exclusion of other causes of infantile epilepsy. |
| 10. Treatment | No curative treatment. Anticonvulsants (infantile spasm regimens such as ACTH, vigabatrin, valproic acid). Palliative symptomatic treatment. Fever management is important (seizures worsen with high fever). Gene therapy at an early stage of preclinical research. |
| 11. Prognosis | Extremely poor. Most remain severely disabled from infancy through childhood. Survival for several years has been reported in some patients, but seizure control is difficult. High mortality. |
| 12. Prevention | Carrier genetic counseling, prenatal diagnosis (ST3GAL5 analysis), PGT-M. Carrier screening for the founder variant in the Amish population. |
| 13. References | Simpson et al. 2004 and 9 other references |
GM3 gangliosidosis is a very rare disease caused by deficiency of a ganglioside biosynthetic enzyme; it was recognized as an independent disease when the American neurogeneticist Michael A. Simpson and colleagues first identified its molecular cause in 2004. Clinically, since before 1987, pediatric patients with severe infantile epilepsy, neurodevelopmental regression, and abnormal skin keratinization had been reported in clusters within the North American Old Order Amish community, and the condition had been called "Amish infantile epilepsy syndrome (AIES)." The Amish are a religious community living in Pennsylvania, Ohio, and elsewhere in the United States; descended from an isolated small founder population, they have a markedly higher frequency of certain rare genetic diseases than the general population.
In 2004, Simpson et al. identified a homozygous nonsense variant (p.Arg288Ter) in the ST3GAL5 gene (former name: SIAT9), located on chromosome 2 (2p11.2), through linkage analysis and sequencing in families of patients with AIES. ST3GAL5 encodes the enzyme (lactosylceramide α-2,3-sialyltransferase, SAT-I) that synthesizes GM3 ganglioside by transferring sialic acid to lactosylceramide (LacCer). Because GM3 is an essential precursor for the synthesis of a-series complex gangliosides such as GM2, GM1, and GD1a, in ST3GAL5 deficiency, GM3 and all downstream complex gangliosides are lost simultaneously from neurons.
This discovery was the first case showing that, unlike GM1 and GM2 gangliosidoses, in which gangliosides accumulate due to deficiency of ganglioside-degrading enzymes, GM3 gangliosidosis is a disease in which gangliosides are depleted due to deficiency of a ganglioside-synthesizing enzyme. This confirmed that the spectrum of ganglioside metabolic diseases encompasses both storage and depletion diseases. Subsequently, other pathogenic ST3GAL5 variants have been reported in patients of various non-Jewish, non-Amish ethnicities beyond the Amish, and several dozen cases have now accumulated worldwide.
GM3 gangliosidosis occurs when pathogenic variants arise in both alleles of the ST3GAL5 gene, resulting in loss of function of GM3 synthase (lactosylceramide α-2,3-sialyltransferase, SAT-I or GM3 synthase). GM3 synthase is located in the Golgi membrane and, in the glycolipid synthesis pathway, catalyzes the reaction that synthesizes GM3 (NeuAcα2-3Galβ1-4Glcβ1-1Cer) by transferring sialic acid (N-acetylneuraminic acid, NeuAc) to lactosylceramide (LacCer) via an α-2,3 linkage.
GM3 is the very first sialic acid-containing intermediate of ganglioside biosynthesis and serves as the essential precursor for the synthesis of all complex gangliosides, including complex a-series gangliosides (GM2→GM1→GD1a→GT1a), b-series gangliosides (GD3→GD2→GD1b→GT1b→GQ1b), and c-series gangliosides. Therefore, in ST3GAL5 deficiency, synthesis of all complex gangliosides downstream of GM3 (GM1, GM2, GD1a, GD1b, GT1b, etc.) is completely blocked. This is a fundamentally different mechanism from the classic gangliosidoses previously defined as storage diseases caused by blocked degradation of specific gangliosides, and it means that GM3 gangliosidosis is a ganglioside deficiency disease.
While GT3, GD3, and GM3 are all lost, lactosylceramide, the substrate of the enzyme, may actually increase. As components of lipid rafts in neuronal membranes, gangliosides play essential roles in receptor signal transduction, neurotrophic factor binding (TrkA, TrkB receptors), synapse formation and maintenance, nerve regeneration, and regulation of ion channel function. Complete deficiency of all complex gangliosides, including GM3, severely impairs both the structural integrity and functional signal transduction of neurons.
The ST3GAL5 gene (formerly named SIAT9) is located on the short arm of chromosome 2 (2p11.2) and consists of 10 exons. The coding sequence is about 1,131 bp and produces a type II transmembrane protein of 376 amino acids. The ST3GAL5 protein has the structure of a type II membrane protein with its C-terminus oriented toward the lumen of the Golgi membrane and acts as a functional monomer or dimer.
The mode of inheritance is autosomal recessive. The founder variant in the Amish population is p.Arg288Ter (c.862C>T), a nonsense variant that truncates the enzymatically active domain of the ST3GAL5 protein. This variant has a high carrier frequency within the Amish community due to a founder effect, and almost all Amish patients are homozygous for it. In non-Amish patients, various missense, splicing, frameshift, and large deletion variants have been reported, and their number continues to grow.
Besides the ST3GAL5 gene, there are ST3GAL1–ST3GAL6, which belong to the same ST3(Gal) sialyltransferase enzyme family, but because their substrate specificities for glycolipids and glycoproteins differ, they cannot compensate for the role of ST3GAL5. Therefore, ST3GAL5 deficiency alone results in complete loss of GM3 and all a-, b-, and c-series complex gangliosides. In ganglioside biosynthesis, deficiencies of B4GALNT1 (GM2/GD2 synthase, GM2 synthase) and ST8SIA1 (GD3 synthase), in addition to ST3GAL5, also cause related diseases, but because ST3GAL5 deficiency blocks the most basal step, its clinical phenotype is the most severe.
In genetic counseling, carrier couples have a 25% risk of an affected child with each pregnancy, and caution is needed in the Amish population because the carrier frequency of the founder variant is high. Molecular carrier testing, prenatal diagnosis, and PGT-M are available.
GM3 gangliosidosis is an extremely ultra-rare disease with only a few dozen cases reported worldwide. Based on literature searches through 2024, a total of no more than 30–50 patients are estimated to have been reported. A substantial portion of these are from the Old Order Amish population living in Pennsylvania, Ohio, Indiana, and elsewhere in the United States, with a prominent clustering due to a founder effect.
The prevalence in the Amish population is markedly higher than in the general population, but specific figures are unknown. In non-Amish populations, individual family cases have been reported from various countries, including Brazil, Italy, Turkey, Japan, and China, suggesting sporadic occurrence worldwide without predilection for any particular ethnicity. In Korea, there are no officially published cases to date, or only very few.
Because of its extreme rarity, epidemiological statistics are virtually nonexistent, and there are no systematic incidence or prevalence data. Diagnosis of this disease requires prior clinical suspicion and access to ganglioside metabolic analysis and genetic testing, so the number of undiagnosed patients is presumed to exceed the number of reported patients. In Korea, it falls within the scope of ultra-rare disease designation (Special Copayment Reduction V117).
Gangliosides are acidic glycosphingolipids containing one or more sialic acids; they are distributed in the cell membranes of all vertebrates but are most abundant in the nervous system, especially in neuronal membranes of the brain. In lipid raft microdomains of neuronal membranes, gangliosides participate in clustering and regulation of signal transduction of receptors (EGFR, TrkA/B/C, PDGFR, etc.), regulation of synaptic vesicle function, cell adhesion and migration, and amplification of neurotrophic factor signaling. GM1, GD1a, GD1b, and GT1b account for about 95% of the total ganglioside content of the brain, and all of them use GM3 as a precursor.
When GM3 synthesis is blocked by ST3GAL5 deficiency, none of the a-series (GM3→GM2→GM1→GD1a→GT1a→GQ1b) and b-series (GM3→GD3→GD2→GD1b→GT1b→GQ1b) gangliosides are produced. As a result, gangliosides are completely lost from neuronal membranes in the brain, and because there is no compensating mechanism, severe neuronal dysfunction results. In particular, because GM1 and GD1a amplify TrkA/TrkB receptor signaling of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), their loss leads to reduced neurotrophic support. Because GT1b plays an important role in synaptic transmission, its loss is associated with synaptic dysfunction.
Proposed mechanisms by which ganglioside deficiency contributes to epilepsy include dysregulation of neuronal membrane Na⁺/K⁺-ATPase, GABA receptor dysfunction, and dysregulated membrane insertion of ion channels. In addition, abnormal lipid raft structure due to ganglioside loss may disrupt the functional clustering of various membrane receptors and ion channels, causing an overall increase in neuronal excitability. Because gangliosides also play an important role in the differentiation of skin keratinocytes, hyperkeratosis (ichthyosis-like skin changes) is understood to occur in ST3GAL5 deficiency.
Demyelination or abnormal myelination is also observed pathologically. Gangliosides are known to contribute to myelin formation and maintenance, so white matter abnormalities occur in deficiency. The white matter signal abnormalities and abnormal brain development seen on brain MRI reflect this.
The clinical symptoms of GM3 gangliosidosis are characterized by severe infantile neurological regression beginning within the first few months after birth and are divided into the following main clinical domains.
Neurological symptoms: the most prominent symptom is severe infantile epilepsy. In most patients, infantile spasms (West syndrome) beginning between 2 and 6 months of age appear, followed by progression to polymorphic seizures (multifocal, generalized clonic, tonic seizures). The seizures are refractory epilepsy that responds poorly to standard anticonvulsants, and status epilepticus recurs. Meanwhile, heat sensitivity is a highly characteristic clinical finding of GM3 gangliosidosis, with elevated body temperature or heat stimuli acting as factors that worsen or trigger seizures. This has been reported as a particularly prominent feature in the Amish patient population.
Psychomotor developmental regression is also pronounced. Initially development is normal or mildly delayed, and then developmental regression accelerates after the onset of seizures. Most patients do not achieve gross motor milestones such as head control and sitting, or regress after achieving them. Language development is absent or severely limited. Hypertonia and spastic quadriplegia develop, and in some, hypotonia precedes them early on.
Skin symptoms: ichthyosiform hyperkeratosis is observed in many patients. Dry skin and scale-like hyperkeratosis appear particularly on the limbs and trunk. This is presumed to be because gangliosides are involved in keratinocyte differentiation.
Visual symptoms: visual fixation and tracking are impaired, with accompanying nystagmus. Corneal opacity has been reported in some patients. A cherry-red spot is not observed, which is a clinical point of distinction from the degradative diseases GM1 and GM2 gangliosidosis.
Neurological signs: spastic quadriplegia, hyperreflexia, and a positive Babinski sign are observed. In some, hypotonia precedes and then converts to spasticity. Involuntary movements or myoclonus may be present. Microcephaly has been reported in some patients.
Electroencephalogram (EEG) findings: hypsarrhythmia is characteristically observed in the infantile spasm stage. Later, multifocal epileptiform discharges and generalized slowing appear, and as the disease progresses, the EEG becomes progressively suppressed (burst suppression).
Brain MRI findings: T2 hyperintense lesions of the white matter (abnormal myelination/demyelination) are observed. Abnormal brain development (agenesis of the corpus callosum, abnormal cerebral cortical development) is confirmed in some patients. Progressive brain atrophy is present. Structural abnormalities of the basal ganglia have also been reported.
Skin signs: ichthyosis-like skin changes—a dry, scale-like thickened stratum corneum, particularly prominent in the limb flexures and trunk—are observed. Skin biopsy may show ganglioside-related abnormalities within keratinocytes.
Plasma and red cell membrane ganglioside analysis: all complex gangliosides, including GM3, are markedly reduced or absent, and the substrate lactosylceramide is found to be increased. This biochemical pattern is highly specific for GM3 gangliosidosis and plays an important role in establishing the diagnosis.
Absence of cherry-red spot: unlike GM1 and GM2 gangliosidoses, no cherry-red spot is observed. This reflects that GM3 gangliosidosis is a disease of ganglioside deficiency rather than ganglioside accumulation (→ swelling of macular ganglion cells).
Because of its extremely rare incidence and the technical limitations of newborn screening, there is currently no standardized newborn screening for GM3 gangliosidosis. Lysosomal enzyme activity is normal, and there is no abnormal excretion of urine oligosaccharides or mucopolysaccharides, so it cannot be detected by existing metabolic screening methods.
Screening in the Amish population: in the Old Order Amish community, carrier testing for the ST3GAL5 founder variant (p.Arg288Ter) before planned pregnancy or in early pregnancy is recommended to prevent affected pregnancies. Such testing is provided through medical facilities within the Amish population and collaborating genetics clinics.
Clinical screening clues: when infantile spasms, refractory infantile epilepsy, heat-induced seizures, and ichthyosis-like skin changes occur together in children of Amish descent or in non-Amish populations, GM3 gangliosidosis should immediately be included in the differential diagnosis. Plasma ganglioside analysis and ST3GAL5 gene analysis are performed selectively.
Methodologies for measuring ganglioside metabolites based on tandem mass spectrometry for future expanded newborn screening are being studied but have not reached the stage of standardization.
GM3 gangliosidosis is confirmed by the combination of ganglioside profile analysis and ST3GAL5 genetic testing.
Ganglioside analysis: the ganglioside profile is analyzed in plasma or red cell membranes (red blood cell ghosts) by high-performance liquid chromatography (HPLC) or mass spectrometry (LC-MS/MS). In GM3 gangliosidosis, a characteristic pattern is found in which all major gangliosides, including GM3, GM2, GM1, GD1a, GD1b, and GT1b, are markedly reduced or absent and the precursor lactosylceramide (LacCer) is increased. This biochemical pattern is the core basis of the diagnosis. Ganglioside analysis after skin fibroblast culture or direct measurement of ST3GAL5 enzyme activity is also possible.
Molecular genetic testing: pathogenic variants on both alleles are identified by NGS or Sanger sequencing of the ST3GAL5 gene. In Amish patients, the homozygous p.Arg288Ter variant can be quickly confirmed by targeted testing.
Brain MRI and EEG: as diagnostic aids, brain MRI confirms white matter abnormalities, abnormal brain development, and brain atrophy, and EEG confirms hypsarrhythmia and multifocal epileptiform discharges. These findings are not specific for GM3 gangliosidosis but strongly support the clinical diagnosis.
Differential diagnosis: differentiation is needed from other causes of infantile spasms (tuberous sclerosis, West syndrome, pyridoxine-dependent epilepsy, ACTH-responsive epilepsy, etc.) and other neurometabolic diseases (GM1 and GM2 gangliosidoses—findings of ganglioside accumulation, pyruvate dehydrogenase deficiency, mitochondrial diseases, etc.). The absence of a cherry-red spot, ganglioside deficiency (not accumulation), and ST3GAL5 variants are key to differentiation.
As of 2026, there is no established curative treatment for GM3 gangliosidosis. The focus of treatment is seizure control and symptomatic supportive care.
Anticonvulsant treatment: administration of ACTH (adrenocorticotropic hormone) or vigabatrin, the standard treatments for infantile spasms, is attempted as first-line therapy. However, seizures in GM3 gangliosidosis are usually refractory, so response to this treatment is often limited. Combinations of various anticonvulsants, such as valproic acid, levetiracetam, clonazepam, and topiramate, are tried. The ketogenic diet may be tried, as it has shown reduced seizure frequency in some refractory infantile epilepsies.
Fever management: In patients with GM3 gangliosidosis, heat stimuli trigger or worsen seizures, so prompt antipyretic measures (acetaminophen, etc.) and body temperature control are important when fever occurs. Minimizing exposure to hot environments and promptly treating infection-related fever are central to seizure management.
Supportive and rehabilitative care: Physical, occupational and speech therapy support functional maintenance and prevention of complications. Muscle relaxants for spasticity and assistive devices are considered. Oral hygiene to prevent aspiration and nutritional support (gastrostomy tube if needed) are also necessary.
Investigational therapy: AAV-based gene therapy delivering the ST3GAL5 gene is being explored in cell models but is at an early stage of animal model research. Strategies to externally supplement the ganglioside synthesis pathway (e.g., exogenous ganglioside supply) are also being explored theoretically, but the blood-brain barrier is an obstacle to delivering sufficient gangliosides to the central nervous system.
The prognosis of GM3 gangliosidosis is extremely poor. Nearly all reported patients develop severe neurodevelopmental disability, intractable epilepsy and neurodegeneration, and early mortality is high. Many patients die in infancy to childhood from complications such as status epilepticus, respiratory failure and aspiration pneumonia, with age at death ranging from several months to several years.
Analysis of early cases in the Amish population reported that most patients died before age 5 or survived with profound neurological impairment. Longer survival has been reported in some non-Amish patients, which may reflect the diversity of the phenotypic spectrum. Seizure control is the most important prognostic factor for long-term survival, but seizures are mostly intractable and difficult to control adequately.
Because disease-modifying strategies such as gene therapy have not yet reached the clinical stage, improvement in prognosis is currently limited. Since applying gene therapy in the presymptomatic period is expected to be most effective for preserving neurological function, linking an early diagnosis system in the Amish population with therapeutic research is important.
Prevention of GM3 gangliosidosis centers on secondary prevention through carrier testing and prenatal diagnosis.
Carrier screening in the Amish population: In Old Order Amish communities, carrier testing for the ST3GAL5 founder variant (p.Arg288Ter) is performed before planned pregnancy. When both parents are carriers, each pregnancy carries a 25% risk of being affected, and options through prenatal diagnosis or PGT-M are available.
Genetic counseling: After a patient is diagnosed, the mode of inheritance (autosomal recessive) and recurrence risk are explained to the parents and siblings, and carrier testing is recommended to the extended family. If a pregnancy is ongoing, the prenatal diagnosis procedure is explained immediately.
Prenatal diagnosis: ST3GAL5 variants are analyzed in fetal DNA obtained by CVS (11–14 weeks) or amniocentesis (15–20 weeks) to determine whether the fetus is affected. Ganglioside profile analysis (after fetal cell culture) is also possible as an adjunct.
Preimplantation genetic testing (PGT-M): A method that excludes affected embryos in conjunction with in vitro fertilization, available when the ST3GAL5 variants of both parents have been identified. It is the most powerful preventive method, preventing an affected pregnancy itself.